![](/images/graphics-bg.png)
Remdesivir for patients with Coronavirus disease 2019 pneumonia requiring high oxygen support
المؤلفون المشاركون
al-Musallamni, Muna A.
al-Ibrahim, Rim S.
Umrani, Ali S.
al-Maqati, Iman Z.
al-Maqati, Muhammad Z. I.
Edbais, Muhammad
Daghfal, Joanne
al-Khatib, Muhammad
المصدر
العدد
المجلد 2022، العدد 3 (31 ديسمبر/كانون الأول 2022)، ص ص. 1-6، 6ص.
الناشر
تاريخ النشر
2022-12-31
دولة النشر
قطر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Background: Treatment options for patients with critical Coronavirus Disease 2019 (COVID-19) are limited.
This study aimed to describe the clinical characteristics and outcomes associated with remdesivir therapy in patients with COVID-19 who require non-invasive (NIV) ventilation or invasive mechanical ventilation (IMV).
Methods: Data were retrospectively extracted for adults with COVID-19 confirmed using polymerase chain reaction (PCR) between August 1, 2020 and January 28, 2021 who received ≥ 48 hours of remdesivir therapy while on NIV or IMV.
Clinical improvement was defined as two-category improvement on an eight-point ordinal severity scale.
Results: A total of 133 individuals were included, of which 114 (85.7%) were on NIV and 19 (14.3%) were on IMV at the time of remdesivir initiation.
The majority of the patients were males (62.4%), and the median age was 56 years.
All the patients received concomitant dexamethasone therapy.
Remdesivir treatment was commenced after a median of 7 days from onset of symptoms and was continued for a median of 5 days.
Clinical improvement within 28 days was achieved in 101 patients (75.9%); among which, 78.1% and 63.2% were subjected to baseline NIV and IMV, respectively.
Among the 11 (8.3%) patients who died of any cause by day 28, 9 (7.9%) and 2 (10.5%) were subjected to baseline NIV and IMV, respectively.
The most frequent adverse events were sinus bradycardia (21, 13.1%) and alanine transaminase increase (18, 11.3%).
Almost all adverse events were classified as Grades 1–3.
Conclusion: The use of remdesivir in combination with systemic corticosteroids is associated with high recovery rates and low all-cause mortality in patients with COVID-19 pneumonia who require NIV or IMV.
The results need confirmation from clinical trials of appropriate design and size.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
al-Ibrahim, Rim S.& al-Maqati, Iman Z.& al-Maqati, Muhammad Z. I.& Edbais, Muhammad& al-Khatib, Muhammad& Daghfal, Joanne…[et al.]. 2022. Remdesivir for patients with Coronavirus disease 2019 pneumonia requiring high oxygen support. Qatar Medical Journal،Vol. 2022, no. 3, pp.1-6.
https://search.emarefa.net/detail/BIM-1437749
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
al-Ibrahim, Rim S.…[et al.]. Remdesivir for patients with Coronavirus disease 2019 pneumonia requiring high oxygen support. Qatar Medical Journal No. 3 (2022), pp.1-6.
https://search.emarefa.net/detail/BIM-1437749
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
al-Ibrahim, Rim S.& al-Maqati, Iman Z.& al-Maqati, Muhammad Z. I.& Edbais, Muhammad& al-Khatib, Muhammad& Daghfal, Joanne…[et al.]. Remdesivir for patients with Coronavirus disease 2019 pneumonia requiring high oxygen support. Qatar Medical Journal. 2022. Vol. 2022, no. 3, pp.1-6.
https://search.emarefa.net/detail/BIM-1437749
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 5-6
رقم السجل
BIM-1437749
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)